 |
|
|
| |
Switching From Boosted Atazanavir Plus Emtricitabine /Tenofovir
Disoproxil Fumarate to a Tenofovir Alafenamide-Based Single-Tablet Regimen: Week-48 Data in Virologically Suppressed Adults
|
| |
| |
Reported by Jules Levin
EACS 2015 Oct 21-24 Bacelona, Spain - 15th European AIDS Conference
B. Rijnders1, C. Stephan2, A. Lazzarin3, K. Squires4, M. McKellar5,
S. Kiertiburanakul6, J.R. Arribas7, J. Gerstoft8, D. Murphy9, M. Bloch10, Y. Liu11, M. Fordyce12, S. McCallister12
1Erasmus MC, Internal Medicine and Infectious Diseases, Rotterdam, Netherlands, 2Universitats Klinikum Frankfurt, Frankfurt, Germany, 3University Vita-Salute San Raffaele, Malattie Infective, Milano, Italy, 4Thomas Jefferson University Hospital, Philadelphia, United States, 5Duke University, Durham, United States, 6Ramathibodi Hospital, Bangkok, Thailand, 7Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, 8Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 9Clinique Médicale l'Actuel, Montreal, Canada, 10Holdsworth House Research, Sydney, Australia, 11Gilead Sciences, Inc., Biometrics, Foster City, United States, 12Gilead Sciences, Inc., Clinical Research, Foster City, United States
|
| |
|
|
|
|
|
